1
|
Arana-Luna LL, Alvarado-Ibarra M, Silva-Michel LG, Morales-Maravilla A, González-Rubio MDC, Chávez-Aguilar LA, Tena-Iturralde MF, Mojica-Balceras L, Zapata-Canto N, Galindo-Delgado P, Miranda-Madrazo MR, Morales-Hernández AE, Silva-Vera K, Grimaldo-Gómez FA, Hernández-Caballero Á, Bates-Martín RA, Álvarez-Vera JL, Tepepa-Flores F, Teomitzi-Sánchez Ó, Fermín-Caminero DJ, de la Peña-Celaya JA, Salazar-Ramírez Ó, Flores-Villegas LV, Guerra-Alarcón LV, Leyto-Cruz F, Inclán-Alarcón SI, Milán-Salvatierra AI, Ventura-Enríquez Y, Pérez-Lozano U, Báez-Islas PE, Tapia-Enríquez AL, Palma-Moreno OG, Aguilar-Luevano J, Espinosa-Partida A, Pérez-Jacobo LF, Rojas-Castillejos F, Ruiz-Contreras JI, Loera-Fragoso SJ, Medina-Coral JE, Acosta-Maldonado BL, Soriano-Mercedes EJ, Saucedo-Montes EE, Valero-Saldana LM, González-Prieto SG, Nava-Villegas L, Hernández-Colín AK, Hernández-Alcántara AE, Zárate-Rodríguez PA, Ignacio-Ibarra G, Meillón-García LA, Espinosa-Bautista KA, Ledesma-de la Cruz C, Barbosa-Loría DM, García-Castillo C, Balderas-Delgado C, Cabrera-García Á, Pérez-Zúñiga JM, Hernández-Ruiz E, Villela-Peña A, Gómez Cortés SC, Romero-Rodelo H, Garzón-Velásquez KB, Serrano-Hernández C, Martínez-Ríos A, Pedraza-Colín ML, Martínez-Coronel JA, Narváez-Davalos IM, García-Camacho AS, Merino-Pasaye LE, Aguilar-Andrade C, Aguirre-Domínguez JA, Guzmán-Mera PG, Delgado-de la Rosa E, Flores López PE, González-Aguirre LL, Ramírez-Alfaro EM, Vera-Calderón H, Meza-Dávalos ML, Murillo-Cruz J, Pichardo-Cepín YM, Ramírez-Romero EF. Consenso de leucemia mieloide aguda en México. GAC MED MEX 2022. [DOI: 10.24875/gmm.m21000597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
2
|
Arana-Luna LL, Alvarado-Ibarra M, Silva-Michel LG, Morales-Maravilla A, González-Rubio MDC, Chávez-Aguilar LA, Tena-Iturralde MF, Mojica-Balceras L, Zapata-Canto N, Galindo-Delgado P, Miranda-Madrazo MR, Morales-Hernández AE, Silva-Vera K, Grimaldo-Gómez FA, Hernández-Caballero Á, Bates-Martín RA, Álvarez-Vera JL, Tepepa-Flores F, Teomitzi-Sánchez Ó, Fermín-Caminero DJ, de la Peña-Celaya JA, Salazar-Ramírez Ó, Flores-Villegas LV, Guerra-Alarcón LV, Leyto-Cruz F, Inclán-Alarcón SI, Milán-Salvatierra AI, Ventura-Enríquez Y, Pérez-Lozano U, Báez-Islas PE, Tapia-Enríquez AL, Palma-Moreno OG, Aguilar-Luevano J, Espinosa-Partida A, Pérez-Jacobo LF, Rojas-Castillejos F, Ruiz-Contreras JI, Loera-Fragoso SJ, Medina-Coral JE, Acosta-Maldonado BL, Soriano-Mercedes EJ, Saucedo-Montes EE, Valero-Saldana LM, González-Prieto SG, Nava-Villegas L, Hernández-Colín AK, Hernández-Alcántara AE, Zárate-Rodríguez PA, Ignacio-Ibarra G, Meillón-García LA, Espinosa-Bautista KA, Ledesma-de la Cruz C, Barbosa-Loría DM, García-Castillo C, Balderas-Delgado C, Cabrera-García Á, Pérez-Zúñiga JM, Hernández-Ruiz E, Villela-Peña A, Gómez Cortés SC, Romero-Rodelo H, Garzón-Velásquez KB, Serrano-Hernández C, Martínez-Ríos A, Pedraza-Colín ML, Martínez-Coronel JA, Narváez-Davalos IM, García-Camacho AS, Merino-Pasaye LE, Aguilar-Andrade C, Aguirre-Domínguez JA, Guzmán-Mera PG, Delgado-de la Rosa E, Flores López PE, González-Aguirre LL, Ramírez-Alfaro EM, Vera-Calderón H, Meza-Dávalos ML, Murillo-Cruz J, Pichardo-Cepín YM, Ramírez-Romero EF. Consensus in acute myeloid leukemia in Mexico. GAC MED MEX 2022; 158:M1-M48. [DOI: 10.24875/gmm.m21000598] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
|
3
|
Gamboa-Aguilar J, Zamorano-Montaño ÁC, Enríquez-Osorio A, Torres-Cubillas W, López-Arroyo JL, Chapol JAM, Zurita-Martínez H, Pascual JR, Saldaña-Campos E, Rojas-Castillejos F, Madera-Maldonado CE, Peñafiel COR, Maldonado EB, Rascón RG, Hernández-Juárez J, Silos-Briones G, Domínguez SDLM, Pérez-Ramírez ÓDJ, Sosa-Camas RE, Romero-López C, Guzmán-Chores L, Amador-Sánchez R, Ledesma-de la Cruz C, Campos-Cabrera G, Ramírez-Chávez LL, Esparza-García JC, Vela-Ojeda J, García-Chávez J, González-Trejo JJ, Rodríguez-Mejorada SM, Rosado-Castro RA, de Arredondo RASM, Pérez-Hernández VH, Majluf-Cruz K, Domínguez-Reyes V, Arreola-Diaz R, Alvarado-Moreno JA, Majluf-Cruz A. Abo Blood Group, Atherothrombotic Comorbidities, and COVID-19: A Case-Control Study of their Association in the Mexican Population. Arch Med Res 2021; 53:100-108. [PMID: 34649737 PMCID: PMC8504860 DOI: 10.1016/j.arcmed.2021.09.005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2021] [Revised: 08/25/2021] [Accepted: 09/23/2021] [Indexed: 01/10/2023]
Abstract
Background COVID-19 has been associated with negative results in patients with A blood group and with a better evolution in O blood group individuals. Aim Because the evidence regarding ABO blood groups and COVID was empirically not that clear in our country, we tested the association regarding COVID-19 and blood groups. Material and Methods Adult patients were enrolled in this prospective, case-control, observational multicenter study. Patients with a confirmed diagnosis of COVID-19 were assigned to one of three groups based on the clinical presentation of the infection. Age, gender, ABO and Rh blood groups, body mass index, history of diabetes mellitus or high blood pressure, and smoking were recorded directly or from their clinical charts. ABO blood group was obtained from 5,000 blood donors (50% each gender). Atherothrombotic variables were compared with a nation-wide data collection. Results A total of 2,416 patients with COVID-19 were included (women:39.6%; men:60.4%). There were no significant differences between cases and controls in terms of age. O blood group was the most frequently found in healthy donors and COVID-19 patients, but this blood group was significantly higher in COVID-19 patients vs. healthy donors. ABO blood group was not associated with the final health status in COVID-19 patients. Obesity, diabetes mellitus, hypertension and smoking were significantly more frequent among COVID-19 patients. Conclusion The proposed protective effect of the O blood group in COVID-19 patients could not be reproduced in the Mexican population while some atherothrombotic risk factors had a significant effect on the clinical evolution.
Collapse
Affiliation(s)
- Jacqueline Gamboa-Aguilar
- Laboratorio Central, Hospital General Regional No. 2, El Marqués, Instituto Mexicano del Seguro Social, Querétaro, Querétaro, México
| | - Ángela Carele Zamorano-Montaño
- Laboratorio Central, Hospital General Regional No. 2, El Marqués, Instituto Mexicano del Seguro Social, Querétaro, Querétaro, México
| | - Aldo Enríquez-Osorio
- Laboratorio Central, Hospital General Regional No. 2, El Marqués, Instituto Mexicano del Seguro Social, Querétaro, Querétaro, México
| | - Wendoline Torres-Cubillas
- Laboratorio Central, Hospital de Especialidades Antonio Fraga Mouret, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - José Luis López-Arroyo
- Hospital General B, Instituto Seguridad y Servicios Sociales de los Trabajadores del Estado, Ciudad Juárez, Chihuahua, México
| | | | - Hugo Zurita-Martínez
- Hospital Juan Graham, Secretaría de Salud de Tabasco, Villahermosa, Tabasco, México
| | | | - Eli Saldaña-Campos
- Hospital Juan Graham, Secretaría de Salud de Tabasco, Villahermosa, Tabasco, México
| | - Flavio Rojas-Castillejos
- Servicio de Hematología, Hospital General con Especialidades, Secretaría de Salud, Salina Cruz, Oaxaca, México
| | | | - Christian Omar Ramos Peñafiel
- Servicio de Hematología, Hospital Regional de Alta Especialidad de Ixtapaluca, Secretaría de Salud. Ixtapaluca, Estado de México, México
| | - Emanuel Bermeo Maldonado
- Dirección Quirúrgica, Hospital Regional de Alta Especialidad de Ixtapaluca, Secretaría de Salud, Ixtapaluca, Estado de México, México
| | - Rafael García Rascón
- Servicio de Medicina Interna, Hospital Regional de Alta Especialidad de Ixtapaluca, Secretaría de Salud. Ixtapaluca, Estado de México, México
| | - Jesús Hernández-Juárez
- CONACYT-Facultad de Odontología, Universidad Autónoma Benito Juárez de Oaxaca, Oaxaca, Oaxaca, México
| | - Graciela Silos-Briones
- Servicio de Hematología, Hospital General de Zona No. 50, Instituto Mexicano del Seguro Social, San Luis Potosí, San Luis Potosí, México
| | | | | | - Rosa Elena Sosa-Camas
- Servicio de Medicina Interna, Hospital General de Hermosillo, Hermosillo, Sonora, México
| | - Cuauhtémoc Romero-López
- Unidad de Terapia Intensiva, Hospital Universitario de Puebla, Benemérita Universidad Autónoma de Puebla, Puebla, Puebla, México
| | - Laura Guzmán-Chores
- Servicio de Hematología, Hospital General Regional Carlos MacGregor Sánchez Navarro, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Raquel Amador-Sánchez
- Servicio de Hematología, Hospital General Regional Carlos MacGregor Sánchez Navarro, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Cindy Ledesma-de la Cruz
- Servicio de Hematología, Hospital General Regional Carlos MacGregor Sánchez Navarro, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | | | | | - Juan Carlos Esparza-García
- Banco de Sangre, Hospital General Regional Carlos MacGregor Sánchez Navarro, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Jorge Vela-Ojeda
- Departamento de Hematología, Unidad Médica de Alta Especialidad, Hospital Especialidades, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Jaime García-Chávez
- Departamento de Hematología, Unidad Médica de Alta Especialidad, Hospital Especialidades, Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - José Joaquín González-Trejo
- Servicio de Medicina Transfusional, Hospital General Dr. Belisario Domínguez, Instituto Seguridad y Servicios Sociales de los Trabajadores del Estado, Tuxtla Gutiérrez, Chiapas, México
| | | | | | | | - Víctor Hugo Pérez-Hernández
- Servicio de Hematología, Hospital General de Zona Nueva Frontera, Instituto Mexicano del Seguro Social, Tapachula, Chiapas, México
| | - Karim Majluf-Cruz
- Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Víctor Domínguez-Reyes
- Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Rodrigo Arreola-Diaz
- Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - José Antonio Alvarado-Moreno
- Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México
| | - Abraham Majluf-Cruz
- Unidad de Investigación Medica en Trombosis, Hemostasia y Aterogenesis, Instituto Mexicano del Seguro Social, Ciudad de México, México.
| |
Collapse
|
4
|
Ignacio-Ibarra G, García-Lee MT, González-Ávila AI, García-Chávez J, Guzmán-Chores L, Cruz CLDL, Lugo-García Y, Juárez-Lara J, García-Vázquez M, Madera-Maldonado CE, Ramos-Peñafiel CO, Majluf-Cruz A. A proposal for the management of COVID-19-induced coagulopathy in adults. GAC MED MEX 2021; 157:201-206. [PMID: 34270538 DOI: 10.24875/gmm.20000930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022] Open
Abstract
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the cause of the coronavirus disease 2019 (COVID-19) pandemic, which has a high case fatality rate. Most severely ill patients develop a special type of coagulopathy that had not been described before and that is now considered the main cause of death. For this reason, anticoagulant treatment has become one of the cornerstones of the treatment of this infection. However, the rate at which the evidence regarding the use of anticoagulants is generated is quite fast, and sometimes it is difficult to interpret and conflicting. After having performed an extensive review of the published literature, this proposal for the use of anticoagulant treatment is made, taking into account available resources in Mexico.
Collapse
Affiliation(s)
- Gregorio Ignacio-Ibarra
- Hematology Department, Hospital General Regional No. 1 "Carlos MacGregor Sánchez Navarro", Instituto Mexicano del Seguro Social, Mexico City
| | - Ma Teresa García-Lee
- Hematology Department, Hospital General Regional No. 1 "Carlos MacGregor Sánchez Navarro", Instituto Mexicano del Seguro Social, Mexico City
| | - Ana I González-Ávila
- Hematology Department, Hospital General Regional No. 1 "Carlos MacGregor Sánchez Navarro", Instituto Mexicano del Seguro Social, Mexico City
| | - Jaime García-Chávez
- Hematology Department, High Specialty Medical Unit, Hospital de Especialidades "Eduardo Fraga Mouret", Centro Médico Nacional La Raza, Instituto Mexicano del Seguro Social, Mexico City
| | - Laura Guzmán-Chores
- Hematology Department, Hospital General Regional No. 1 "Carlos MacGregor Sánchez Navarro", Instituto Mexicano del Seguro Social, Mexico City
| | - Cindy Ledesma-de la Cruz
- Hematology Department, Hospital General Regional No. 1 "Carlos MacGregor Sánchez Navarro", Instituto Mexicano del Seguro Social, Mexico City
| | - Yolanda Lugo-García
- Hematology Department, Hospital General Regional No. 1 "Carlos MacGregor Sánchez Navarro", Instituto Mexicano del Seguro Social, Mexico City
| | - Jessi Juárez-Lara
- Hematology Department, Hospital General Regional No. 1 "Carlos MacGregor Sánchez Navarro", Instituto Mexicano del Seguro Social, Mexico City
| | - Mauricio García-Vázquez
- Hematology Department, Hospital General Regional No. 1 "Carlos MacGregor Sánchez Navarro", Instituto Mexicano del Seguro Social, Mexico City
| | - Cristina E Madera-Maldonado
- Hematology Department, Ixtapaluca High Specialty Regional Hospital, Secretaría de Salud, Ixtapaluca, State of Mexico
| | - Christian O Ramos-Peñafiel
- Hematology Department, Ixtapaluca High Specialty Regional Hospital, Secretaría de Salud, Ixtapaluca, State of Mexico
| | - Abraham Majluf-Cruz
- Hematology Department, Hospital General Regional No. 1 "Carlos MacGregor Sánchez Navarro", Instituto Mexicano del Seguro Social, Mexico City.,Thrombosis, Hemostasis and Atherogenesis Medical Research Unit, Hospital General Regional No. 1 "Carlos MacGregor Sánchez Navarro", Instituto Mexicano del Seguro Social, Mexico City. Mexico
| |
Collapse
|